Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
Language: Английский
Biology, Journal Year: 2025, Volume and Issue: 14(2), P. 129 - 129
Published: Jan. 26, 2025
Neurodegenerative disorders (NDs) cause progressive neuronal loss and are a significant public health concern, with NDs projected to become the second leading global of death within two decades. Huntington’s disease (HD) is rare, ND caused by an autosomal-dominant mutation in huntingtin (HTT) gene, severe brain resulting debilitating motor, cognitive, psychiatric symptoms. Given complex pathology HD, biomarkers essential for performing early diagnosis, monitoring progression, evaluating treatment efficacy. However, identification consistent HD challenging due prolonged premanifest stage, HD’s heterogeneous presentation, its multiple underlying biological pathways. This study involves 10-year bibliometric analysis biomarker research, revealing key research trends gaps. The also features comprehensive literature review emerging biomarkers, concluding need better stratification patients well-designed longitudinal studies validate biomarkers. Promising candidate wet biomarkers— including neurofilament light chain protein (NfL), microRNAs, mutant HTT protein, specific metabolic inflammatory markers— discussed, emphasis on their potential utility stage. Additionally, reflecting structural deficits motor or behavioral impairments, such as neurophysiological (e.g., tapping, speech, EEG, event-related potentials) imaging MRI, PET, diffusion tensor imaging) evaluated. findings underscore that discovery validation reliable urgently require improved patient studies. Reliable particularly crucial optimizing clinical management strategies, enabling personalized approaches, advancing trials HD-modifying therapies.
Language: Английский
Citations
0
Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
Language: Английский
Citations
0